NeOnc Technologies, Quazar Investment to close $50M partnership by Oct. 23

NeOnc Technologies (NTHI) announced a significant milestone in its partnership with Quazar Investment. Following the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates, the closing of the previously announced $50M strategic partnership is mandated to occur no later than October 23rd, 2025, as stipulated by the definitive signed agreement. The finalization of these administrative requirements in the UAE officially starts the countdown for the funding to be completed. The partnership is centered around the Abu Dhabi-based operating subsidiary NuroCure, which is overseen by NeOnc’s wholly-owned holding company, NuroMENA Holdings Ltd. The collaboration is designed to launch and scale clinical trials, regulatory filings, and infrastructure development across the UAE and the broader Middle East and North Africa region. NuroMENA Holdings was officially incorporated in the Abu Dhabi Global Market on August 6, 2025, a key step that satisfied all contingencies for the finalization of the $50M collaboration with Quazar Investment. This strategic partnership will help accelerate the development of NeOnc’s therapeutic pipeline, including its NEO100 and NEO212 clinical programs. The strategic agreement with Quazar involves a significant equity investment in NeOnc. A portion of the funds, $15M, is specifically allocated for the Phase 2B clinical trials and infrastructure development in the UAE and the wider MENA region. The partnership will leverage the UAE’s advanced clinical trial infrastructure, including facilities like the Cleveland Clinic Abu Dhabi, which operates under U.S. FDA protocols.